In dose-finding clinical study, it is common that multiple endpoints are of interest. For instance, efficacy and toxicity endpoints are both primary in clinical trials. In this article, we propose a joint model for correlated efficacy-toxicity outcome constructed with Archimedean Copula, and extend the continual reassessment method (CRM) to a bivariate trial design in which the optimal dose for phase III is based on both efficacy and toxicity. Specially, considering numerous cases that continuous and discrete outcomes are observed in drug study, we will extend our joint model to mixed correlated outcomes. We demonstrate through simulations that our algorithm based on Archimedean Copula model has excellent operating characteristics
International audiencePhase I oncology clinical trials are designed to identify the optimal dose tha...
Many formal statistical procedures for phase I dose-finding studies have been proposed. Most concern...
In many phase I trials, the design goal is to find the dose associated with a certain target toxicit...
In dose-finding clinical study, it is common that multiple endpoints are of interest. For instance, ...
In recent years, there has been an increasing interest in developing dose finding methods incorporat...
Drug combination trials are increasingly common nowadays in clinical research. However, very few met...
In recent years, there has been an increasing interest in developing dose finding methods incorporat...
In this dissertation we work on two problems. In the first problem we propose a general framework fo...
This dataset contains information on the outcomes observed at each dose-level in a large number of d...
Bivariate meta-analysis provides a useful framework for combining information across related studies...
This research examines new design approaches for Phase I clinical trials, which are designed to stud...
Comment: Journal of the Royal Statistical Society. Series C: Applied Statistics 59 (3), pp. 543-544 ...
Bivariate meta‐analysis provides a useful framework for combining information across related studies...
International audiencePhase I oncology clinical trials are designed to identify the optimal dose tha...
Correlations among survival endpoints are important for exploring surrogate endpoints of the true en...
International audiencePhase I oncology clinical trials are designed to identify the optimal dose tha...
Many formal statistical procedures for phase I dose-finding studies have been proposed. Most concern...
In many phase I trials, the design goal is to find the dose associated with a certain target toxicit...
In dose-finding clinical study, it is common that multiple endpoints are of interest. For instance, ...
In recent years, there has been an increasing interest in developing dose finding methods incorporat...
Drug combination trials are increasingly common nowadays in clinical research. However, very few met...
In recent years, there has been an increasing interest in developing dose finding methods incorporat...
In this dissertation we work on two problems. In the first problem we propose a general framework fo...
This dataset contains information on the outcomes observed at each dose-level in a large number of d...
Bivariate meta-analysis provides a useful framework for combining information across related studies...
This research examines new design approaches for Phase I clinical trials, which are designed to stud...
Comment: Journal of the Royal Statistical Society. Series C: Applied Statistics 59 (3), pp. 543-544 ...
Bivariate meta‐analysis provides a useful framework for combining information across related studies...
International audiencePhase I oncology clinical trials are designed to identify the optimal dose tha...
Correlations among survival endpoints are important for exploring surrogate endpoints of the true en...
International audiencePhase I oncology clinical trials are designed to identify the optimal dose tha...
Many formal statistical procedures for phase I dose-finding studies have been proposed. Most concern...
In many phase I trials, the design goal is to find the dose associated with a certain target toxicit...